about
ABL tyrosine kinases: evolution of function, regulation, and specificityA unique set of SH3-SH3 interactions controls IB1 homodimerization.A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinaseKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsSyndapin--a membrane remodelling and endocytic F-BAR proteinSignal transduction in the chronic leukemias: implications for targeted therapiesIdentification of small molecules that disrupt signaling between ABL and its positive regulator RIN1Abelson kinase acts as a robust, multifunctional scaffold in regulating embryonic morphogenesis.C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.Functional mechanisms and roles of adaptor proteins in abl-regulated cytoskeletal actin dynamics.ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.Identification of N-terminal lobe motifs that determine the kinase activity of the catalytic domains and regulatory strategies of Src and Csk protein tyrosine kinases.Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.Fusion protein containing SH3 domain of c-Abl induces hepatocarcinoma cells to apoptosis.Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsThe BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemiaDisruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.Inhibiting kinases in malignant gliomas.Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseOrientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.Treatment for chronic myelogenous leukemia: the long road to imatinibApplying the discovery of the Philadelphia chromosome.Protein kinases as targets for cancer treatment.Aberrant cytokine signaling in leukemia.Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaNUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitorsMolecular biology of bcr-abl1-positive chronic myeloid leukemia.An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.Molecular and cellular bases of chronic myeloid leukemia.ABL1 fusion genes in hematological malignancies: a review.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.
P2860
Q24299738-66AE92E0-6412-490E-8E05-F6BCCEF15F42Q24541394-791D3601-2C02-43E6-A0AC-1AF4A09A9BC2Q24563301-50A9BD0E-C752-45CE-AF4A-1F064DD3DB4CQ26849792-9F1B4A72-7C44-46C6-946B-DB7D3A69A20CQ27006727-E71A075B-A3A9-432B-8043-852872A7F12FQ27026031-0CDD6D09-4BF9-4900-9245-9A44D3E6D881Q28545055-18329947-4B3A-46CB-91E3-AECBFDA75A5AQ30008895-5FEC439D-1EC2-4390-AE0E-0F44DF29D7CDQ30009935-1430D9FA-6486-48AB-BFF7-392D39DC6D37Q30010077-FED6F189-3602-42CA-8EB5-09E742B71CA9Q30155948-84979805-372F-46B3-AB44-76543705D0E6Q30157342-8F6FA6EC-C543-4495-BBAD-8978F4B1C6B5Q30157519-F7E83840-BC7F-4939-BA00-DCFB92B7B31CQ30157957-E5CC42FF-A4C4-48BC-AAFB-8A8E9172ED76Q30159676-1E556CDD-FB64-4093-994C-29DB3104A762Q30480984-610ADD73-49DC-4302-8E21-F567CA926EBEQ33828334-BEE58E35-19A5-445A-8A52-22576DCC9ACCQ35071103-F255C4A1-1DA4-4B5B-9022-A820AC6E0C73Q35221149-4C39B3F8-AE6B-45AE-9FBA-26E489E1B9D4Q35553592-313BB99B-167E-4961-97FD-8530D0C960E4Q35615838-DF558CE1-2543-4A14-BE29-BF8B15D6461EQ35885308-3F917E30-2454-49EC-AEB6-8869A2B354AAQ36210636-12F0DAF1-CC86-4C12-A1D3-C38A62B03F0EQ36436853-00FBC39D-F9CD-44E5-AC9F-685288D852BBQ36764876-AE942886-2EF1-4684-A34E-C63308ACDC9BQ36780139-AF556AF4-C060-4BBD-8E98-D93E528BC5ECQ36843762-87594D5A-6CC2-4170-B23E-C6FFD38E9A0CQ36853551-7981014A-CAC0-425A-A5AA-71E1FF63DB30Q36900105-1B55893F-39FA-4BB0-B79C-3783AEA73D62Q36900109-ACAE9AC1-4430-4A79-98C3-8E389C10F739Q36918131-E39E4C1A-21EE-4AEA-8794-AAE39415C60CQ36970192-501E1832-F006-4E4B-97E8-A0CE6D8E30DDQ36997520-774402CD-F85D-460B-BFCC-97380A5B44E1Q37216300-9AB21125-E289-4FF3-9AC0-AE7518DC85B5Q37283128-F5B8AABD-C7A1-44D4-A6E1-7E21CF4C7982Q37334825-12391001-387D-4522-B0EA-28A5CE835874Q37697852-3E2D96FB-006B-44B6-9D35-6090C490EB96Q37825832-9A7127D2-EB46-4399-8557-8DC508996E19Q37857340-B49190F1-58A1-4452-A50C-CB955F7C39F3Q37919976-ACE0743C-7F35-4053-B0BE-D3C4A282A1CD
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Autoinhibition of Bcr-Abl through its SH3 domain.
@ast
Autoinhibition of Bcr-Abl through its SH3 domain.
@en
type
label
Autoinhibition of Bcr-Abl through its SH3 domain.
@ast
Autoinhibition of Bcr-Abl through its SH3 domain.
@en
prefLabel
Autoinhibition of Bcr-Abl through its SH3 domain.
@ast
Autoinhibition of Bcr-Abl through its SH3 domain.
@en
P2093
P1433
P1476
Autoinhibition of Bcr-Abl through its SH3 domain.
@en
P2093
Kristen M Smith
Richard A Van Etten
Rinat Yacobi
P356
10.1016/S1097-2765(03)00274-0
P577
2003-07-01T00:00:00Z